Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDSA NASDAQ:GELS NASDAQ:PASG NASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDSAEdesa Biotech$2.40+0.8%$2.06$1.55▼$5.59$16.71M0.3934,630 shs6,882 shsGELSGelteq$1.87+2.2%$1.83$0.77▼$5.50$17.27MN/A193,178 shs80,271 shsPASGPassage Bio$5.73-0.9%$7.53$5.12▼$26.60$18.03M1.6769,939 shs166,187 shsWINTWindtree Therapeutics$1.02+4.9%$0.73$0.36▼$737.44$3.56M0.725.01 million shs14.72 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDSAEdesa Biotech-2.06%+5.31%+19.00%+1.28%-51.03%GELSGelteq-6.15%+7.65%+16.56%-21.12%+182,999,900.00%PASGPassage Bio+1.94%+3.96%-13.68%-11.08%-65.22%WINTWindtree Therapeutics-2.74%+8.07%+143.15%-16.87%-99.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEDSAEdesa Biotech1.5049 of 5 stars2.05.00.00.00.61.70.6GELSGelteqN/AN/AN/AN/AN/AN/AN/AN/APASGPassage Bio2.5637 of 5 stars3.52.00.00.00.62.51.3WINTWindtree Therapeutics2.9728 of 5 stars3.05.00.00.02.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDSAEdesa Biotech 4.00Strong Buy$5.00108.33% UpsideGELSGelteq 0.00N/AN/AN/APASGPassage Bio 3.00Buy$150.002,517.80% UpsideWINTWindtree Therapeutics 2.00Hold$350.0034,213.73% UpsideCurrent Analyst Ratings BreakdownLatest WINT, PASG, GELS, and EDSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$5.006/24/2025PASGPassage BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDSAEdesa BiotechN/AN/AN/AN/A$0.61 per shareN/AGELSGelteq$100K176.53N/AN/A$1.30 per share1.44PASGPassage BioN/AN/AN/AN/A$19.84 per shareN/AWINTWindtree TherapeuticsN/AN/AN/AN/A$38.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-187.01%-78.72%8/8/2025 (Estimated)GELSGelteq-$2.33MN/A0.00∞N/AN/AN/AN/AN/APASGPassage Bio-$64.77M-$20.40N/AN/AN/AN/A-93.59%-59.65%8/14/2025 (Estimated)WINTWindtree Therapeutics-$1.79M-$823.47N/AN/AN/AN/A-227.93%-56.46%8/18/2025 (Estimated)Latest WINT, PASG, GELS, and EDSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PASGPassage Bio-$0.20N/AN/AN/AN/AN/A8/8/2025N/AEDSAEdesa Biotech-$0.23N/AN/AN/AN/AN/A5/15/2025Q1 2025WINTWindtree Therapeutics-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/A5/13/2025Q1 2025PASGPassage Bio-$4.80-$5.00-$0.20-$0.25N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEDSAEdesa BiotechN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/APASGPassage BioN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDSAEdesa BiotechN/A15.7215.72GELSGelteqN/A0.79N/APASGPassage BioN/A3.743.74WINTWindtree TherapeuticsN/A0.250.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDSAEdesa Biotech5.50%GELSGelteqN/APASGPassage Bio53.48%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipEDSAEdesa Biotech22.60%GELSGelteqN/APASGPassage Bio5.00%WINTWindtree Therapeutics0.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDSAEdesa Biotech207.02 million5.44 millionNot OptionableGELSGelteqN/A9.44 millionN/AN/APASGPassage Bio1303.12 million2.96 millionOptionableWINTWindtree Therapeutics303.66 million3.65 millionNot OptionableWINT, PASG, GELS, and EDSA HeadlinesRecent News About These CompaniesWindtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury StrategyJuly 24 at 9:00 AM | globenewswire.comWindtree Shares Soar More Than 100% on BNB Treasury PlansJuly 19, 2025 | msn.comNasdaq Biotech Firm Windtree to Raise $200M for First-Ever BNB Crypto Treasury0July 18, 2025 | thecurrencyanalytics.comTBiotech Company Windtree to Raise Up to $200M for BNB TreasuryJuly 17, 2025 | coindesk.comBNB gains 3% following Windtree's plan to launch BNB treasury, H1 reportJuly 16, 2025 | fxstreet.comWindtree Becomes First NASDAQ Firm to Add BNB to Its Balance SheetJuly 16, 2025 | blockonomi.comWindtree to raise $200M to launch a BNB treasury strategyJuly 16, 2025 | msn.comWindtree Therapeutics, Inc. Announces $60 Million Securities Purchase Agreement to Launch BNB Crypto Treasury StrategyJuly 16, 2025 | quiverquant.comQWindtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On SubscriptionsJuly 16, 2025 | globenewswire.comWindtree Therapeutics Announces U.S. Patent Grant for Istaroxime in Acute Heart Failure Treatment - NasdaqJuly 4, 2025 | nasdaq.comWindtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart FailureJuly 2, 2025 | globenewswire.comWindtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim AnalysisJune 30, 2025 | finance.yahoo.comWindtree Therapeutics Signs Agreement to Cut PHEXXI Manufacturing Costs by Over 50% Through Partnership with Chinese ManufacturerJune 26, 2025 | quiverquant.comQWindtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive GelJune 26, 2025 | globenewswire.comWindtree Therapeutics Announces Promising Phase 2 Study Results for IstaroximeJune 17, 2025 | msn.comWindtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B StudyJune 16, 2025 | manilatimes.netMWindtree Therapeutics Receives $7 Million Offer for Preclinical Oncology PlatformJune 14, 2025 | msn.comWindtree Therapeutics: Windtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 13, 2025 | finanznachrichten.deWindtree Receives Offer for Its Preclinical Oncology Drug CandidateJune 11, 2025 | tmcnet.comWindtree Therapeutics, Inc. Secures $7 Million Up Front for Preclinical Oncology Drug Candidate, Potentially Worth $130 Million in Milestones and $1.5 Billion in RoyaltiesJune 11, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeWINT, PASG, GELS, and EDSA Company DescriptionsEdesa Biotech NASDAQ:EDSA$2.40 +0.02 (+0.84%) Closing price 03:53 PM EasternExtended Trading$2.58 +0.18 (+7.50%) As of 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Gelteq NASDAQ:GELS$1.87 +0.04 (+2.19%) As of 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Passage Bio NASDAQ:PASG$5.73 -0.05 (-0.87%) Closing price 04:00 PM EasternExtended Trading$6.26 +0.52 (+9.16%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.Windtree Therapeutics NASDAQ:WINT$1.02 +0.05 (+4.87%) Closing price 04:00 PM EasternExtended Trading$1.01 -0.01 (-0.98%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.